Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | FDPS | P14324 | 1/20 | 0.50 |
| ▸ | CDK4 | P11802 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | GPR39 | O43194 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | MAT2A | P31153 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17700463 | 0.82 | ALDH1A1 (0.50) | ALDH1A1FDPSCDK4CDK2HPGD | |
| SCHEMBL9278154 | 0.79 | ACACB (0.36) | ALDH1A1FDPSCDK4CDK2GPR39 | |
| SCHEMBL2564257 | 0.77 | ALDH1A1 (0.62) | ALDH1A1FDPSHPGDHDAC1HDAC8 | |
| SCHEMBL9278638 | 0.76 | ALDH1A1 (0.54) | ALDH1A1FDPSGPR39HPGDIDH1 | |
| SCHEMBL25683769 | 0.76 | ACACB (0.40) | FDPSCDK4CDK2HDAC1HDAC6 | |
| SCHEMBL19552131 | 0.76 | NPC1 (0.42) | FDPSCDK4CDK2HDAC1HDAC6 | |
| SCHEMBL91472 | 0.74 | CDK4 (0.46) | ALDH1A1CDK4CDK2 | |
| SCHEMBL1274368 | 0.74 | CXCR4 (0.55) | ALDH1A1FDPSHPGD | |
| SCHEMBL29552506 | 0.74 | CXCR4 (0.55) | ALDH1A1FDPSHPGD | |
| SCHEMBL2296005 | 0.73 | ALDH1A1 (0.50) | ALDH1A1FDPSHPGDIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | claimed |
| EP-4267131-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR PARASITIC DISEASES | CELGENE CORPORATION (US) | 2023-11-01 | — | — | EP | claimed |
| WO-2022146920-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR PARASITIC DISEASES | CELGENE CORPORATION (US) | 2022-07-07 | — | — | WO | claimed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
| EP-4267131-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR PARASITIC DISEASES | CELGENE CORPORATION (US) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022146920-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR PARASITIC DISEASES | CELGENE CORPORATION (US) | 2022-07-07 | — | — | WO | disclosed |
| CN-109415321-B | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2022-06-17 | — | — | CN | disclosed |
| EP-3031799-B1 | AROMATIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-9776962-B2 | Aromatic compounds with GPR40 agonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-03 | — | — | US | disclosed |
| EP-3031799-A1 | AROMATIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-06-15 | — | — | EP | disclosed |
| US-20160115128-A1 | AROMATIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115128-A1 | AROMATIC COMPOUND | GLP1R, GPR119, GPR39 | ALDH1A1 3137/4885FDPS 3138/4885CDK4 2846/4885 |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | ALDH1A1 3927/4885FDPS 985/4885CDK4 2367/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | ALDH1A1 3927/4885FDPS 985/4885CDK4 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.